CN111714598A - Traditional Chinese medicine composition for treating overactive bladder and preparation process and application thereof - Google Patents
Traditional Chinese medicine composition for treating overactive bladder and preparation process and application thereof Download PDFInfo
- Publication number
- CN111714598A CN111714598A CN202010721853.XA CN202010721853A CN111714598A CN 111714598 A CN111714598 A CN 111714598A CN 202010721853 A CN202010721853 A CN 202010721853A CN 111714598 A CN111714598 A CN 111714598A
- Authority
- CN
- China
- Prior art keywords
- parts
- overactive bladder
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating overactive bladder, a preparation process and application thereof, wherein the composition comprises, by mass, 40-60 parts of Chinese yam, 20-30 parts of astragalus, 20-30 parts of codonopsis pilosula, 20-30 parts of fried bighead atractylodes rhizome, 15-25 parts of poria cocos, 10-20 parts of rhizoma alismatis and 15-25 parts of rhizoma smilacis glabrae. The pharmacodynamic result shows that the combination can obviously improve the overactive bladder and can be used for treating the overactive bladder.
Description
Technical Field
The invention belongs to the field of medicines, relates to a traditional Chinese medicine composition, and particularly relates to a traditional Chinese medicine composition for treating overactive bladder.
Background
Overactive bladder (OAB) refers to the involuntary contraction of the detrusor muscle, which is manifested primarily as frequent, urgent and nocturnal micturition with or without urge incontinence. In recent years, with the progress of China into aging society and the increase of diabetes and nervous system damage diseases, the incidence rate of the secondary related diseases, namely overactive bladder, is also increased year by year.
Currently, the current practice is. Clinically, tolterodine tartrate (hereinafter referred to as sertraline) is only used for treating symptoms of frequent micturition, urgent micturition or urge incontinence caused by overactive bladder, but the sertraline has certain toxic and side effects in clinical use, for example, after the sertraline is used for treatment, light and moderate anticholinergic effects, such as dry mouth, dyspepsia, tear reduction and the like, can be caused. The traditional Chinese medicine composition is a traditional Chinese medicine preparation, has the characteristic of high safety, and meanwhile, no traditional Chinese medicine composition for treating overactive bladder is available in the market.
Disclosure of Invention
Aiming at the problems, the invention provides a traditional Chinese medicine composition for treating overactive bladder, which is prepared from traditional Chinese medicines and can be used for treating overactive bladder. The invention provides a traditional Chinese medicine composition for treating overactive bladder, which comprises the following raw materials in parts by mass:
40-60 parts of Chinese yam, 20-30 parts of astragalus, 20-30 parts of codonopsis pilosula, 20-30 parts of fried bighead atractylodes rhizome, 15-25 parts of poria cocos, 10-20 parts of rhizoma alismatis and 15-25 parts of rhizoma smilacis glabrae.
Particularly, the raw materials comprise the following components in parts by mass:
45-55 parts of Chinese yam, 22-28 parts of astragalus, 22-28 parts of codonopsis pilosula, 22-28 parts of fried bighead atractylodes rhizome, 17-23 parts of poria cocos, 12-18 parts of rhizoma alismatis and 17-23 parts of rhizoma smilacis glabrae.
Particularly, the raw materials comprise the following components in parts by mass:
50 parts of Chinese yam, 25 parts of astragalus, 25 parts of codonopsis pilosula, 25 parts of fried bighead atractylodes rhizome, 20 parts of poria cocos, 15 parts of rhizoma alismatis and 20 parts of rhizoma smilacis glabrae.
The preparation process of the traditional Chinese medicine composition comprises the following steps: decocting the astragalus root with 10 times of water for 3 times, 2 hours each time, filtering, combining the filtrates, and concentrating to obtain thick paste with the relative density of 1.30-1.35 (60 ℃) for later use; decocting the other six medicinal materials with 10 times of water for 2 times, each time for 2 hours, filtering, combining filtrates, standing, taking supernatant, concentrating into fluid extract with the relative density of 1.06-1.10 (60 ℃), adding one time of ethanol, stirring, refrigerating for 12-48 hours, filtering to take supernatant, recovering ethanol, concentrating into thick paste with the relative density of 1.30-1.35 (60 ℃), combining with the thick paste, drying (60 ℃), pulverizing into fine powder, adding an appropriate amount of silica gel powder, mixing uniformly, granulating with 90% ethanol, drying, and finishing to prepare 1000 granules.
The composition is found to be capable of obviously improving the overactive bladder in animal experiments and clinical researches.
Compared with the prior art, the traditional Chinese medicine composition for treating overactive bladder provided by the invention has the following advantages: 1. is prepared by adopting traditional Chinese medicines, and has no toxic or side effect; 2. has better curative effect, can fundamentally solve the symptoms and can not relapse.
Drawings
FIG. 1 is a graph showing the effect of urine stabilizing capsules on urodynamics of overactive bladder in rats.
Detailed Description
For further understanding of the purpose, function, and technical solutions of the present invention, the present invention will now be described in detail with reference to the following embodiments.
Example 1:
a traditional Chinese medicine composition for treating overactive bladder comprises the following raw materials in parts by mass:
50 parts of Chinese yam, 25 parts of astragalus, 25 parts of codonopsis pilosula, 25 parts of fried bighead atractylodes rhizome, 20 parts of poria cocos, 15 parts of rhizoma alismatis and 20 parts of rhizoma smilacis glabrae.
The preparation process of the traditional Chinese medicine composition comprises the following steps: decocting the astragalus root with 10 times of water for 3 times, 2 hours each time, filtering, combining the filtrates, and concentrating to obtain thick paste with the relative density of 1.30-1.35 (60 ℃) for later use; decocting the other six medicinal materials with 10 times of water for 2 times, each time for 2 hours, filtering, combining filtrates, standing, taking supernatant, concentrating into fluid extract with the relative density of 1.06-1.10 (60 ℃), adding one time of ethanol, stirring, refrigerating for 12-48 hours, filtering to take supernatant, recovering ethanol, concentrating into thick paste with the relative density of 1.30-1.35 (60 ℃), combining with the thick paste, drying (60 ℃), pulverizing into fine powder, adding an appropriate amount of silica gel powder, mixing uniformly, granulating with 90% ethanol, drying, and finishing to prepare 1000 granules.
In order to confirm the effectiveness of the traditional Chinese medicine composition provided by the invention, the research on the therapeutic action of cyclophosphamide-induced overactive bladder in rats is carried out, and the results are as follows:
1 materials and instruments
1.1 Experimental animals
SPF SD rat, male, 60, body mass 250 ~ 280g, provided by Liaoning Biotechnology GmbH, license number: SCXK (Liao) 2015 + 0001, the animals are adaptively raised in an animal room for one week at the temperature of 20-24 ℃ and the humidity of 40-70%, and are alternately illuminated in light and shade for 12 hours, and the animals are maintained to be fed with free drinking water.
1.2 Experimental reagents
Cyclophosphamide is supplied by shanghai yu biotechnology limited; tolterodine tartrate tablets are produced by Shandong Lunan fibrate pharmaceuticals, Inc.; rat Nerve Growth Factor (NGF) ELISA kits were produced by Wuhan's Molsak Biotech Ltd; the rat interleukin 1 beta (IL-1 beta) ELISA kit is provided by Shanghai enzyme-linked biotechnology, Inc.; malondialdehyde (MDA) determination kit (TBA method) and total superoxide dismutase (SOD) determination kit (WST-1 method) are provided by Nanjing Bioengineering research institute.
1.3 Experimental instruments
BL-420E + biological function experiment system, Gengtai Union science and technology Limited; koutopu metering intelligent constant flow pump, Chongqing koutopu peristaltic pump, Inc.; full wavelength microplate reader, Biotek corporation; hand-held high speed homogenizer, Shanghai Bajiu industries, Inc.; BS124S electronic balance, beijing sydolis instruments systems limited; 3-18k low temperature high speed refrigerated centrifuge, Sigma; XPX-9052MBE digital display stainless steel electric heating incubator, Shanghai Boxun industries, Inc.
2 method
2.1 grouping administration and establishment of animal model
60 SD male rats are randomly divided into 6 groups according to the weight, 6 normal control groups, 14 cyclophosphamide (75mg/kg) model groups and 10 administration groups respectively, wherein the groups are a urine stabilizing capsule high dose group (5.4mg/kg), a urine stabilizing capsule medium dose group (2.7mg/kg), a urine stabilizing capsule low dose group (1.35mg/kg) and a positive control tolterodine tablet (0.5 mg/kg). Rats are raised in cages and fed with water through a conventional diet. Rat overactive bladder model was simulated by intraperitoneal injection of cyclophosphamide (75mg/kg) in rats, 3/1 times a day, 4 times in total. After molding for 1h, respectively intragastrically administering high, medium and low concentration urine-stabilizing capsules (1.35, 2.7 and 5.4mg/kg) and positive control tolterodine (0.5mg/kg), 1 time/day, and continuously administering for 14 days.
2.2 Observation index
2.2.1 general status of rats
The general conditions of the rats including body weight, hair, mental state, oral and nasal bleeding, hematuria, etc. were observed during the experiment.
2.2.2 determination of urodynamic index in rats
Urodynamic index detection was performed on rats after the last dose. The abdominal cavity of the rat is injected with 10% chloral hydrate for anesthesia, then the supine position is fixed, the abdomen and the urethral orifice are disinfected, the epidural anesthesia catheter is used for self-producing the rat catheter, and the rat is used as a urethral intubation tube to lead out the residual urine in the bladder and then the catheter is fixed. The abdomen was dissected longitudinally up the upper edge of the rat phalangeal arch to expose the bladder, a small hole was punctured in the top of the bladder, two PE-50 catheters were inserted into the bladder, and purse string sutures were applied to secure the catheters to the bladder without leakage of urine. The fistulization tube 1 is connected with a BL-420E + biological function experiment system, the fistulization tube 2 is connected with a peristaltic pump, the system is adjusted to zero after residual air is exhausted, urine is completely exhausted from the abdomen by slight pressure, and the bladder basic pressure is adjusted to a baseline. The bladder was perfused with warm saline (perfusion rate 0.1 ml/min). Recording urodynamic oscillogram, peak value of urination pressure (mmHg) and urination interval time(s). At least 3 urination cycles were recorded. At the end of the assay, the catheter was connected to a syringe to aspirate the residual urine in the bladder and the residual urine volume (ml) was recorded. After the experiment is finished, rat bladder tissues are taken, the wet weight (mg) of the bladder is weighed and recorded, and the bladder index is calculated as follows:
bladder index (%) - (wet bladder weight (mg)/rat body weight (g) x 100%
2.2.3 determination of NGF content in rat serum
After urodynamic determination, the rat is bled through the abdominal aorta, and the supernatant is centrifuged and frozen at-80 ℃ for later use. The change in the amount of nerve growth factor in rat serum was determined by ELISA method exactly according to the instructions. Measuring SOD, MDA and IL-1 beta contents in rat bladder tissue, collecting blood, quick freezing with liquid nitrogen, and freezing at-80 deg.C. Collecting appropriate amount of bladder tissue, adding ice physiological saline, placing in ice bath, homogenizing with tissue homogenizer, centrifuging to obtain supernatant, centrifuging at 4 deg.C for 10min at 3500 r/min. Taking a proper amount of supernatant, determining the content of IL-1 beta in the bladder tissue supernatant strictly according to the requirements of the ELISA kit specification, and determining the contents of SOD and MDA in the bladder tissue supernatant strictly according to the requirements of the kit specification.
2.3 statistical treatment
All experimental data were performed using SPSS 17.0 software. According to the normality and the homogeneity of the variance of the data of the test data, each group of data is represented by x +/-s, and the difference between the groups is compared by adopting a t test for the significance. P <0.05 is statistically significant.
3 results
3.1 general conditions in rats
The model-making rats have different degrees of general symptoms, such as the decline of physique, the reduction of food intake, dark and massive hair loss, listlessness and laziness, bleeding of mouth, nose and eyes and the appearance of macroscopic hematuria. General symptoms of each administration group
The same degree of improvement.
3.2 measurement results of urodynamic index of rat
The bladder of the rat in the control group is in a low-pressure state in the filling period, the bladder pressure in the urination period obviously rises and gradually decreases along with the urination activity, and the rat has a regular urodynamic waveform; compared with a control group, the detrusor unstable contraction occurs in the bladder filling period of the rat in the model group, the contraction frequency is obviously increased, and an irregular sawtooth-shaped pattern is formed; compared with the model group, the waveform of each administration group is improved to different degrees, wherein the high-dose group of the urine stabilizing capsule and the positive medicine group are closer to the urodynamic waveform of the normal group. The urodynamic waveforms for each group are shown in figure 1. Compared with a control group, the rats in the model group have significant differences (P <0.01) in urination interval time shortening, peak value reduction of urination pressure, increase of residual urine volume of bladder and bladder index increase; compared with the model group, the high-dose group of the urine-stabilizing capsule and the positive control group can prolong the urination interval time, increase the peak value of the urination pressure and reduce the residual urine volume of the bladder, and have significant difference (P <0.01) and can reduce the bladder index (P < 0.05). The urodynamic index measurements are shown in Table 1.
(FIG. 1A: normal control group; FIG. 1B: cyclophosphamide model group; FIG. 1C: positive drug tolterodine control group; FIG. 1D: urine stabilizing capsule high dose group; FIG. 1E: urine stabilizing capsule medium dose group; FIG. 1F: urine stabilizing capsule low dose group)
TABLE 1 results of the effect of urine-stabilizing capsules on urodynamic index and bladder index of overactive bladder rats (x. + -.s)
Note: # P <0.01 compared to control; p <0.05, P <0.01 compared to model group.
3.3 measurement of NGF, SOD, MDA and IL-1 beta content in rat
Compared with a control group, the NGF content in the blood serum of a rat in a model group is remarkably increased (P <0.01), the MDA and IL-1 beta content in the supernatant of bladder tissues is remarkably increased (P <0.01, P <0.05), and the SOD content is remarkably reduced (P < 0.01); compared with the model group, the high-dose urine-stabilizing capsule group and the positive control group obviously reduce the NGF content in the serum of a rat, reduce the MDA and IL-1 beta contents (P <0.01 and P <0.05) in the supernatant of bladder tissues and obviously increase the SOD content (P < 0.01). The results of the factor measurements are shown in Table 2.
TABLE 2 measurement of the content of factors in overactive bladder rat by the urine-stabilizing capsule (x. + -. s)
Note: # P <0.001 compared to control; p <0.05, P <0.01 compared to model group.
Claims (5)
1. The traditional Chinese medicine composition for treating overactive bladder is characterized by comprising the following raw materials in parts by mass:
40-60 parts of Chinese yam, 20-30 parts of astragalus, 20-30 parts of codonopsis pilosula, 20-30 parts of fried bighead atractylodes rhizome, 15-25 parts of poria cocos, 10-20 parts of rhizoma alismatis and 15-25 parts of rhizoma smilacis glabrae.
2. The traditional Chinese medicine composition for treating overactive bladder according to claim 1, which is characterized by comprising the following raw materials in parts by mass:
45-55 parts of Chinese yam, 22-28 parts of astragalus, 22-28 parts of codonopsis pilosula, 22-28 parts of fried bighead atractylodes rhizome, 17-23 parts of poria cocos, 12-18 parts of rhizoma alismatis and 17-23 parts of rhizoma smilacis glabrae.
3. The traditional Chinese medicine composition for treating overactive bladder according to claim 1, which is characterized by comprising the following raw materials in parts by mass:
50 parts of Chinese yam, 25 parts of astragalus, 25 parts of codonopsis pilosula, 25 parts of fried bighead atractylodes rhizome, 20 parts of poria cocos, 15 parts of rhizoma alismatis and 20 parts of rhizoma smilacis glabrae.
4. The Chinese medicinal composition for treating overactive bladder according to claim 1, which is prepared by the following steps: decocting the astragalus root with 10 times of water for 3 times, 2 hours each time, filtering, combining the filtrates, and concentrating to obtain thick paste with the relative density of 1.30-1.35 (60 ℃) for later use; decocting the other six medicinal materials with 10 times of water for 2 times, each time for 2 hours, filtering, combining filtrates, standing, taking supernatant, concentrating into fluid extract with the relative density of 1.06-1.10 (60 ℃), adding one time of ethanol, stirring, refrigerating for 12-48 hours, filtering to take supernatant, recovering ethanol, concentrating into thick paste with the relative density of 1.30-1.35 (60 ℃), combining with the thick paste, drying (60 ℃), pulverizing into fine powder, adding an appropriate amount of silica gel powder, mixing uniformly, granulating with 90% ethanol, drying, and finishing to prepare 1000 granules.
5. The new use of the Chinese medicinal composition for treating overactive bladder according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010721853.XA CN111714598A (en) | 2020-07-24 | 2020-07-24 | Traditional Chinese medicine composition for treating overactive bladder and preparation process and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010721853.XA CN111714598A (en) | 2020-07-24 | 2020-07-24 | Traditional Chinese medicine composition for treating overactive bladder and preparation process and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111714598A true CN111714598A (en) | 2020-09-29 |
Family
ID=72573419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010721853.XA Pending CN111714598A (en) | 2020-07-24 | 2020-07-24 | Traditional Chinese medicine composition for treating overactive bladder and preparation process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111714598A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104474390A (en) * | 2014-11-19 | 2015-04-01 | 王小龙 | Traditional Chinese medicine for treating overactive bladder and recurrent urethral infection |
| US20170095520A1 (en) * | 2014-03-21 | 2017-04-06 | Dong Wha Pharm. Co., Ltd. | A composition for preventing, treating, and improving of voiding dysfunction comprising extract of Piper longum L. |
-
2020
- 2020-07-24 CN CN202010721853.XA patent/CN111714598A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170095520A1 (en) * | 2014-03-21 | 2017-04-06 | Dong Wha Pharm. Co., Ltd. | A composition for preventing, treating, and improving of voiding dysfunction comprising extract of Piper longum L. |
| CN104474390A (en) * | 2014-11-19 | 2015-04-01 | 王小龙 | Traditional Chinese medicine for treating overactive bladder and recurrent urethral infection |
Non-Patent Citations (1)
| Title |
|---|
| 高贤娴等: "稳尿胶囊对环磷酰胺诱导的大鼠膀胱过度活动症的治疗作用研究", 《人参研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN103405655B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN102846793B (en) | Composition for stagnant blood constitution, and preparation method and application of composition | |
| CN111714598A (en) | Traditional Chinese medicine composition for treating overactive bladder and preparation process and application thereof | |
| CN101085001B (en) | Compound red sage root freezing-dried powder injection containing tanshinol and its preparation method | |
| CN105434840A (en) | Manufacturing method for Chuanshentong preparation | |
| CN111000983A (en) | Medicinal use of new recombinant human interleukin-1 receptor antagonist | |
| CN108653559A (en) | A kind of hypoglycemic composition and its application | |
| CN114452354B (en) | Traditional Chinese medicine composition for wounds, extract and application thereof | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN114344388B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN113171400B (en) | Transdermal absorbent for treating diabetic peripheral neuropathy, preparation method and application thereof | |
| CN112716967B (en) | Traditional Chinese medicine composition for treating type 2 diabetes insulin resistance | |
| CN115708840B (en) | Application of vanilla extract in preparing anti-lung cancer medicine | |
| CN101618157B (en) | Medicine composition for treating autumn-dryness cold and preparation method thereof | |
| CN117159668B (en) | Application of dampness-resolving toxin-vanquishing particles in preparation of medicines for improving skeletal muscle related adverse reactions caused by dexamethasone | |
| CN114010707B (en) | Pharmaceutical composition for treating pulmonary heart disease and preparation method and application thereof | |
| CN101045112B (en) | Method for preparing traditional Chinese medicine composition to treat gynaopathy | |
| CN116999492A (en) | Medicinal liquor for treating gouty arthritis | |
| CN101559196A (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN101084997B (en) | Traditional Chinese medicine freezing-dried powder injection for treating cardiovascular and cerebrovascular diseases and its preparing method | |
| CN117442698A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating exopathogenic pestilential qi | |
| CN115969950A (en) | Traditional Chinese medicine composition for preventing and treating diabetic peripheral neuropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200929 |